NO20006457L - Vaksine-indusert hepatitt B viral stamme og anvendelser derav - Google Patents
Vaksine-indusert hepatitt B viral stamme og anvendelser deravInfo
- Publication number
- NO20006457L NO20006457L NO20006457A NO20006457A NO20006457L NO 20006457 L NO20006457 L NO 20006457L NO 20006457 A NO20006457 A NO 20006457A NO 20006457 A NO20006457 A NO 20006457A NO 20006457 L NO20006457 L NO 20006457L
- Authority
- NO
- Norway
- Prior art keywords
- hepatitis
- virus
- major
- surface antigen
- amino acid
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title abstract 4
- 208000002672 hepatitis B Diseases 0.000 title abstract 3
- 230000003612 virological effect Effects 0.000 title 1
- 241000700721 Hepatitis B virus Species 0.000 abstract 6
- 239000000427 antigen Substances 0.000 abstract 6
- 102000036639 antigens Human genes 0.000 abstract 6
- 108091007433 antigens Proteins 0.000 abstract 6
- 241000700605 Viruses Species 0.000 abstract 3
- 238000001514 detection method Methods 0.000 abstract 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 abstract 2
- 125000000539 amino acid group Chemical group 0.000 abstract 2
- 230000000890 antigenic effect Effects 0.000 abstract 2
- 230000007423 decrease Effects 0.000 abstract 2
- 230000028993 immune response Effects 0.000 abstract 2
- 208000015181 infectious disease Diseases 0.000 abstract 2
- 206010059193 Acute hepatitis B Diseases 0.000 abstract 1
- 239000004475 Arginine Substances 0.000 abstract 1
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 239000004471 Glycine Substances 0.000 abstract 1
- 208000037628 acute hepatitis B virus infection Diseases 0.000 abstract 1
- 150000001413 amino acids Chemical group 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 abstract 1
- 239000000969 carrier Substances 0.000 abstract 1
- 230000030833 cell death Effects 0.000 abstract 1
- 231100000433 cytotoxic Toxicity 0.000 abstract 1
- 230000001472 cytotoxic effect Effects 0.000 abstract 1
- 230000035876 healing Effects 0.000 abstract 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 abstract 1
- 230000036039 immunity Effects 0.000 abstract 1
- 239000003550 marker Substances 0.000 abstract 1
- 231100000350 mutagenesis Toxicity 0.000 abstract 1
- 230000003472 neutralizing effect Effects 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
- 125000003729 nucleotide group Chemical group 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000004936 stimulating effect Effects 0.000 abstract 1
- 239000006228 supernatant Substances 0.000 abstract 1
- 210000005253 yeast cell Anatomy 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
- G01N33/5761—Hepatitis B
- G01N33/5764—Hepatitis B surface antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C12Q1/706—Specific hybridization probes for hepatitis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Communicable Diseases (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Pathology (AREA)
- Dermatology (AREA)
Abstract
Gjennom denne søknad blir ulike referanser henvist til i parenteser. Beskrivelser av disse publikasjoner i deres helheter blir herved inkorporert som referanse i denne søknad for mer fullt å beskrive fagets status som denne oppfinnelsen dreier seg om. OPPFINNELSENS BAKGRUNN Den foreliggende oppfinnelse dreier seg om hepatitt B-virusgenomet vaksine-indusert mutasjon i aminosyreresten 145 (glycin til arginin) i hovedovertlate- antigenet, dets nukleotidsekvens, de avledede fire hovedproteinsekvenser, antigen, antistoff, deteksjonssystemer, utvikling av effektive vaksiner, og anti-virusmidler. Hepatitt B-virus ble først oppdaget i 1963 som et humant virus som blir over- ført parenteralt. Selv om disse virus ikke er spesielt cytotoksiske og ikke fører til massiv celledød, har de vært årsak til en dominerende infeksjonssykdom som affiserer både voksne og unge barn over hele verden. Tilstedeværelsen av hepatitt B overflateantigen har fungert som den viktigste påvisningsmarkør for bærere av hepatitt B-virus, og derved for de som har risk for å overføre viruset. Tilsvarende indikerer forekomst av et anti-overflateantigen antistoff en immunrespons som ville kunne føre til eventuell helbredelse. Stimulering av en slik immunrespons har i betydelig grad blitt hjulpet av de for øyeblikket lisenserte hepatitt B-vaksiner som er utviklet av Merck Sharpe & Dohme. Disse vaksiner inneholder det dominerende overflateantigen enten i den naturlige (plasma-avledet) eller rekombinante (renset fra gjærceller) former, og de har vist seg å være sikre og effektive i å nøytralisere hepatitt B-viruset. l Singapore har det aktive vaksinasjonsprogram som utføres i en nasjonal skala, resultert i en betydningsfull nedgang i akutt hepatitt B-infeksjon, og insidensen i primær levercellekarsinom. Denne nedgang har videre blitt assosiert med en øket immunitet i befolkningen. Den viktigste antigene epitop i hepatitt B-viruset er en meget høyt konservert region som omfatter 23 aminosyrerester og er lokalisert fra aminosyreposisjon 124 til 147 i det dominerende overflateantigen. Denne lille region som er benevnt som den gruppe-spesifikke determinant «a» er funnet i alle subtyper og alle isolater av hepatitt B-virusgenomene. Dets antigene egenskaper synes å være fremkalt av dets fore-
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/SG1998/000045 WO1999066047A1 (en) | 1998-06-19 | 1998-06-19 | A vaccine-induced hepatitis b viral strain and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20006457D0 NO20006457D0 (no) | 2000-12-18 |
| NO20006457L true NO20006457L (no) | 2001-02-16 |
Family
ID=20429861
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20006457A NO20006457L (no) | 1998-06-19 | 2000-12-18 | Vaksine-indusert hepatitt B viral stamme og anvendelser derav |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US7038035B1 (no) |
| EP (1) | EP1086232A1 (no) |
| JP (1) | JP2002518013A (no) |
| KR (1) | KR100498117B1 (no) |
| CN (1) | CN1255540C (no) |
| AR (1) | AR020092A1 (no) |
| AU (1) | AU756858B2 (no) |
| BG (1) | BG105065A (no) |
| BR (1) | BR9815912A (no) |
| CA (1) | CA2332173A1 (no) |
| HU (1) | HUP0103258A3 (no) |
| IL (1) | IL140363A0 (no) |
| IS (1) | IS5777A (no) |
| MX (1) | MXPA00012724A (no) |
| MY (1) | MY135991A (no) |
| NO (1) | NO20006457L (no) |
| NZ (1) | NZ508892A (no) |
| PL (1) | PL191312B1 (no) |
| TR (1) | TR200003778T2 (no) |
| UA (1) | UA73475C2 (no) |
| WO (1) | WO1999066047A1 (no) |
| YU (1) | YU80500A (no) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPP967999A0 (en) | 1999-04-09 | 1999-05-06 | North Western Health Care Network | Viral variants |
| AUPQ810900A0 (en) | 2000-06-09 | 2000-07-06 | Austin and Repatriation Medical Centre, The | Viral variants and methods of using same |
| CN100355777C (zh) * | 2003-02-10 | 2007-12-19 | 文洪模 | 乙型肝炎病毒pre－S突变蛋白及其制备方法与应用 |
| US20060057670A1 (en) * | 2004-09-10 | 2006-03-16 | The Chinese University Of Hong Kong | Genomic markers of hepatitis B virus associated with hepatocellular carcinomas |
| KR100916992B1 (ko) * | 2004-09-22 | 2009-09-14 | 가부시끼가이샤 센단세메이가가꾸겐큐죠 | Ｂ형 간염 바이러스 ｓ 항원의 검출법 |
| WO2006132598A1 (en) * | 2005-06-07 | 2006-12-14 | Temasek Life Sciences Laboratory Limited | Porcine circovirus type 2 vaccines |
| CN101948932B (zh) * | 2010-07-22 | 2013-04-03 | 中国人民解放军第三〇二医院 | 滚环扩增加跨缺口荧光定量PCR检测乙型肝炎病毒cccDNA试剂盒 |
| CN101948933B (zh) * | 2010-07-22 | 2013-04-03 | 中国人民解放军第三〇二医院 | 检测石蜡包埋肝组织乙型肝炎病毒cccDNA的试剂盒 |
| RU2603729C2 (ru) * | 2015-04-24 | 2016-11-27 | Закрытое акционерное общество научно-производственная компания "Комбиотех" | Рекомбинантная вакцина для профилактики вирусного гепатита в (варианты) |
| RU2586513C1 (ru) * | 2015-04-24 | 2016-06-10 | Закрытое акционерное общество научно-производственная компания "Комбиотех" | РЕКОМБИНАНТНЫЙ ШТАММ ДРОЖЖЕЙ Hansenula polymorpha - ПРОДУЦЕНТ МУТАНТНОГО ПОВЕРХНОСТНОГО АНТИГЕНА ВИРУСА ГЕПАТИТА В (ВАРИАНТЫ) |
| KR20220074917A (ko) | 2019-09-30 | 2022-06-03 | 길리애드 사이언시즈, 인코포레이티드 | Hbv 백신 및 hbv를 치료하는 방법 |
| CN113201051B (zh) * | 2021-04-27 | 2022-08-02 | 复旦大学 | 一种乙肝病毒表面蛋白突变体及其在抗乙肝病毒中的应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9007024D0 (en) * | 1990-03-29 | 1990-05-30 | Imperial College | Novel vaccine |
| US5955089A (en) * | 1993-04-20 | 1999-09-21 | Uab Research Foundation | Strain selection of pneumococcal surface proteins |
| GB9401987D0 (en) | 1994-02-02 | 1994-03-30 | Imperial College | Modified nucleic acid |
| US5830759A (en) * | 1994-08-18 | 1998-11-03 | The Trustees Of Columbia University In The City Of New York | Unique associated Kaposi's sarcoma virus sequences and uses thereof |
| EP0969863A4 (en) | 1996-09-18 | 2001-11-07 | Univ Texas | DEFECTIVE VIRAL INTERFERENCE PARTICLES AND THEIR USE. |
-
1998
- 1998-06-19 UA UA2000127296A patent/UA73475C2/uk unknown
- 1998-06-19 YU YU80500A patent/YU80500A/sh unknown
- 1998-06-19 CN CNB988142007A patent/CN1255540C/zh not_active Expired - Fee Related
- 1998-06-19 AU AU77950/98A patent/AU756858B2/en not_active Ceased
- 1998-06-19 PL PL345203A patent/PL191312B1/pl not_active IP Right Cessation
- 1998-06-19 EP EP19980926022 patent/EP1086232A1/en not_active Withdrawn
- 1998-06-19 US US09/719,533 patent/US7038035B1/en not_active Expired - Fee Related
- 1998-06-19 IL IL14036398A patent/IL140363A0/xx unknown
- 1998-06-19 JP JP2000554856A patent/JP2002518013A/ja active Pending
- 1998-06-19 CA CA002332173A patent/CA2332173A1/en not_active Abandoned
- 1998-06-19 NZ NZ50889298A patent/NZ508892A/xx unknown
- 1998-06-19 MX MXPA00012724A patent/MXPA00012724A/es unknown
- 1998-06-19 WO PCT/SG1998/000045 patent/WO1999066047A1/en not_active Ceased
- 1998-06-19 HU HU0103258A patent/HUP0103258A3/hu not_active Application Discontinuation
- 1998-06-19 KR KR10-2000-7014443A patent/KR100498117B1/ko not_active Expired - Fee Related
- 1998-06-19 BR BR9815912A patent/BR9815912A/pt not_active Application Discontinuation
- 1998-06-19 TR TR200003778T patent/TR200003778T2/xx unknown
-
1999
- 1999-06-17 MY MYPI99002505A patent/MY135991A/en unknown
- 1999-06-18 AR ARP990102961 patent/AR020092A1/es unknown
-
2000
- 2000-12-18 NO NO20006457A patent/NO20006457L/no not_active Application Discontinuation
- 2000-12-18 BG BG105065A patent/BG105065A/xx unknown
- 2000-12-19 IS IS5777A patent/IS5777A/is unknown
-
2006
- 2006-03-20 US US11/385,013 patent/US20070026422A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| PL345203A1 (en) | 2001-12-03 |
| CN1304453A (zh) | 2001-07-18 |
| NZ508892A (en) | 2004-02-27 |
| AU7795098A (en) | 2000-01-05 |
| US20070026422A1 (en) | 2007-02-01 |
| JP2002518013A (ja) | 2002-06-25 |
| IL140363A0 (en) | 2002-02-10 |
| EP1086232A1 (en) | 2001-03-28 |
| AU756858B2 (en) | 2003-01-23 |
| YU80500A (sh) | 2004-05-12 |
| US7038035B1 (en) | 2006-05-02 |
| KR100498117B1 (ko) | 2005-07-01 |
| UA73475C2 (en) | 2005-08-15 |
| PL191312B1 (pl) | 2006-04-28 |
| HUP0103258A2 (hu) | 2001-12-28 |
| BR9815912A (pt) | 2002-02-05 |
| AR020092A1 (es) | 2002-04-10 |
| CA2332173A1 (en) | 1999-12-23 |
| WO1999066047A1 (en) | 1999-12-23 |
| NO20006457D0 (no) | 2000-12-18 |
| TR200003778T2 (tr) | 2001-06-21 |
| MY135991A (en) | 2008-07-31 |
| HUP0103258A3 (en) | 2003-10-28 |
| BG105065A (en) | 2001-09-28 |
| KR20010106128A (ko) | 2001-11-29 |
| CN1255540C (zh) | 2006-05-10 |
| MXPA00012724A (es) | 2003-02-10 |
| IS5777A (is) | 2000-12-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2280690C2 (ru) | Рекомбинантные вирусы гриппа а | |
| Johansson et al. | Dissociation of influenza virus hemagglutinin and neuraminidase eliminates their intravirionic antigenic competition | |
| Del Val et al. | Protection against lethal cytomegalovirus infection by a recombinant vaccine containing a single nonameric T-cell epitope | |
| Geeraedts et al. | Superior immunogenicity of inactivated whole virus H5N1 influenza vaccine is primarily controlled by Toll-like receptor signalling | |
| Muster et al. | Mucosal model of immunization against human immunodeficiency virus type 1 with a chimeric influenza virus | |
| Nara et al. | Neutralization of HIV‐1: a paradox of humoral proportions | |
| Hilleman | Yeast recombinant hepatitis B vaccine | |
| Planz et al. | Specific cytotoxic T cells eliminate cells producing neutralizing antibodies | |
| Britt et al. | Synthesis and processing of the envelope gp55-116 complex of human cytomegalovirus | |
| Stoloff et al. | Synthetic multi‐epitope peptides identified in silico induce protective immunity against multiple influenza serotypes | |
| Ferko et al. | Hyperattenuated recombinant influenza A virus nonstructural-protein-encoding vectors induce human immunodeficiency virus type 1 Nef-specific systemic and mucosal immune responses in mice | |
| Rajčáni et al. | Current developments in viral DNA vaccines: shall they solve the unsolved? | |
| Lifson et al. | Evaluation of the safety, immunogenicity, and protective efficacy of whole inactivated simian immunodeficiency virus (SIV) vaccines with conformationally and functionally intact envelope glycoproteins | |
| Jones et al. | Cellular immune responses in the murine lung to local immunization with influenza A virus glycoproteins in micelles and immunostimulatory complexes (iscoms) | |
| CN107531761A (zh) | 巨细胞病毒抗原及其用途 | |
| AU2001250352A1 (en) | Recombinant influenza A viruses | |
| NO20006457L (no) | Vaksine-indusert hepatitt B viral stamme og anvendelser derav | |
| Wang et al. | The use of an E1-deleted, replication-defective adenovirus recombinant expressing the rabies virus glycoprotein for early vaccination of mice against rabies virus | |
| Norris et al. | CD4+ T helper cells and the role they play in viral control | |
| WO2021207848A1 (en) | Mers-cov vaccine | |
| Bauer et al. | Variants of two major T cell epitopes within the hepatitis B surface antigen are not recognized by specific T helper cells of vaccinated individuals | |
| JP2003230396A (ja) | ｇｐ３５０／２２０非スプライシング変異体 | |
| Shiraki et al. | Construction of Oka varicella vaccine expressing human immunodeficiency virus env antigen | |
| Zhu et al. | A candidate DNA vaccine elicits HCV specific humoral and cellular immune responses | |
| Cox et al. | Immunization of common marmosets with Epstein‐Barr virus (EBV) envelope glycoprotein gp340: Effect on viral shedding following EBV challenge |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |